Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | ADK | P55263 | 6/20 | 0.43 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16803312 | 1.00 | TSHR (0.71) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL8928217 | 1.00 | TSHR (0.71) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL14564902 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL14193124 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL10323532 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL16774560 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL16774561 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL6909337 | 0.84 | LMNA (0.72) | TSHRLMNAMAPTPMP22HBB | |
| Doxifluridine SCHEMBL14564897 | 0.83 | LMNA (1.00) | TSHRLMNAMAPTPMP22HBB | |
| SCHEMBL16774442 | 0.83 | TSHR (0.71) | TSHRLMNAMAPTPMP22HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290535-B2 | Uridine-based gadolinium complex and MRI contrast agent including the same | Korea University Researchand Business Foundation (KR) | 2016-03-22 | — | — | US | disclosed |
| US-20140005369-A1 | URIDINE-BASED GADOLINIUM COMPLEX AND MRI CONTRAST AGENT INCLUDING THE SAME | KOREA BASIC SCIENCE INSTITUTE (KR) | 2014-01-02 | — | — | US | disclosed |
| EP-0770146-A1 | CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996002669-A1 | CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005369-A1 | URIDINE-BASED GADOLINIUM COMPLEX AND MRI CONTRAST AGENT INCLUDING THE SAME | HNRNPUL1, UGP2, HNRNPUL2 | TSHR 2539/4885LMNA 2966/4885MAPT 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.